Back to the clinic as Fox supports trial of NeuroHealing's drooling drug in Parkinson's
This article was originally published in Scrip
The private US firm NeuroHealing Pharmaceuticals has received an undisclosed grant from the Michael J Fox Foundation for Parkinson's Disease (MJFF) to progress a novel formulation of the anti-cholinergic tropicamide for sialorrhoea (uncontrolled drooling) in patients with Parkinson's.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.